Stryker stock faces lower 2026 outlook after Q3 miss
Published on 10/30/2026 at 12:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance cut reshapes investor focus
- Stryker's third-quarter sales grew 7.7%, while adjusted earnings per share rose 10.3% year over year.
- Management lowered its 2026 organic sales and adjusted earnings outlook after results fell short of expectations.
- MedSurg and Neurotechnology outpaced Orthopaedics, highlighting a more uneven growth profile.
Stryker reported third-quarter results on Thursday, October 29, showing solid growth but a weaker outlook for the full year. The medical-device maker said net sales rose 7.7% year over year to USD 6.52 billion, while adjusted earnings per share increased 10.3% to USD 3.52. Both figures fell short of the expectations cited by Morningstar, which reported a revenue forecast of USD 6.62 billion and an adjusted EPS estimate of USD 3.55.
Stryker stock traded at EUR 248.45 on Lang & Schwarz at 12:39 CEST on Friday, October 30, 0.89% above the Xetra close of EUR 246.25 on Thursday, October 29. The real-time quote of Stryker stock reflects the current euro trading venue and is not a substitute for the company's U.S. dollar home-market quotation.
Growth remained uneven across divisions
MedSurg and Neurotechnology generated USD 3.7 billion in sales, up 9.2% on a reported basis and 9.1% organically. Orthopaedics revenue rose 5.7% to USD 2.9 billion, with organic growth of 5.9%. The split leaves the faster-growing MedSurg and Neurotechnology business carrying more of the group's near-term expansion.
Reported net earnings declined 12.3% to USD 753 million, and reported diluted EPS fell 11.7% to USD 1.96 from USD 2.22 a year earlier. Stryker said the quarter included special items such as a USD 293 million goodwill impairment. Excluding specified items, adjusted net earnings rose 10.1% to USD 1.4 billion. Adjusted operating margin expanded 60 basis points to 26.2%, while the reported operating margin was 15.9%.
Lower outlook raises execution pressure
Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted diluted EPS of USD 14.80 to USD 14.90. The previous ranges were 8.3% to 9.3% for organic sales growth and USD 14.95 to USD 15.10 for adjusted EPS, according to Morningstar. The revision shifts investor attention from the company's margin resilience to demand and execution in the final quarter.
Chief Executive Kevin Lobo said the company delivered good overall performance but fell short of its own expectations. He also pointed to expectations for a solid fourth quarter and good momentum heading into 2027. The outlook includes a modestly positive pricing impact, while foreign exchange is expected to provide a slightly favorable contribution if rates remain near current levels.
Stryker repurchased USD 1.0 billion of common stock during the quarter. Its board also approved a USD 3.0 billion increase to the existing share repurchase authorization, giving management additional flexibility while the company works through the slower growth profile.
The broader S&P 500 provides the relevant market backdrop for the U.S.-listed medical-technology company, although the quarterly outlook remains the primary stock-specific issue.
Further earnings commentary and company developments are available in more news and analyses on Stryker stock.
Stryker stock at a glance
- Company: Stryker Corporation
- ISIN: US8636671013
- Home ticker: SYK
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: EUR 248.45 at 12:39 CEST on October 30, 2026
- Xetra close: EUR 246.25 on October 29, 2026
- Third-quarter sales: USD 6.52 billion, up 7.7% year over year
- Adjusted diluted EPS: USD 3.52, up 10.3% year over year
- 2026 adjusted EPS outlook: USD 14.80 to USD 14.90
